Amyloidosis vs Multiple Myeloma: Similarities and Differences in Treatment
Amyloidosis vs Multiple Myeloma: Similarities and Differences in Treatment Read More »
treatments
Standard Treatment: A medical Cocktail
What you can expect. If you have been diagnosed with AL amyloidosis the standard chemotherapy treatment in the United States consists of a 4 drug combination of subcutaneous daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
Standard Treatment: A medical Cocktail Read More »
Bortezomib (VELCADE®)
VELCADE (bortezomib) is a type of chemotherapy called a targeted therapy. VELCADE belongs to a class of medicines called proteasome inhibitors. It is approved by the FDA for the treatment of multiple myeloma and mantle cell lymphoma. VELCADE has been studied in many important clinical trials. It has been studied in a wide range of
Bortezomib (VELCADE®) Read More »
Tafamidis (Vyndamax™) – Treats Cardiomyopathy
Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly.
Tafamidis (Vyndamax™) – Treats Cardiomyopathy Read More »
Vutrisiran (Amvuttra®) – Treats polyneuropathy
In an 18-month clinical study, AMVUTTRA-treated patients showed significant improvement in nerve function and quality of life at 9 months and continued to improve throughout the study, compared with those who received placebo in a similar study. [source: NIH]
Vutrisiran (Amvuttra®) – Treats polyneuropathy Read More »
Dexamethasone (Ozurdex, Maxidex)
The use of cyclophosphamide (Cy), bortezomib (Bor), and dexamethasone (D), the CyBorD regimen, to treat AL amyloidosis, caused by a non-immunoglobulin M (IgM) monoclonal gammopathy, has significantly improved survival outcomes [10]: CyBorD results in a complete hematologic response of 71% and a 1-year OS of 65%
Dexamethasone (Ozurdex, Maxidex) Read More »
Melphalan (Alkeran)
Melphalan belongs to the group of medicines called alkylating agents (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by melphalan, other unwanted effects will also occur.
Melphalan (Alkeran) Read More »
Daratumumab (Darzalex®)
Daratumumab is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. In May 2018, the U.S. Food and Drug Administration (FDA) approved daratumumab for use in combination with bortezomib, melphalan and prednisone to include the treatment of people with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. [source:wikipedia]
Daratumumab (Darzalex®) Read More »